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Motor neurons control blood vessel patterning
in the developing spinal cord
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Formation of a precise vascular network within the central nervous system is of critical
importance to assure delivery of oxygen and nutrients and for accurate functionality of
neuronal networks. Vascularization of the spinal cord is a highly stereotypical process.
However, the guidance cues controlling blood vessel patterning in this organ remain largely
unknown. Here we describe a new neuro-vascular communication mechanism that controls
vessel guidance in the developing spinal cord. We show that motor neuron columns remain
avascular during a developmental time window, despite expressing high levels of the
pro-angiogenic vascular endothelial growth factor (VEGF). We describe that motor neurons
express the VEGF trapping receptor sFlt1 via a Neuropilin-1-dependent mechanism. Using a
VEGF gain-of-function approach in mice and a motor neuron-speciﬁc sFlt1 loss-of-function
approach in chicken, we show that motor neurons control blood vessel patterning by an
autocrine mechanism that titrates motor neuron-derived VEGF via their own expression
of sFlt1.
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R
ecent evidence demonstrates that neuro-vascular commu-
nication is crucial for the development of both the neuronal
and the vascular network within the central nervous system
(CNS)1. Blood vessels control neural stem cell differentiation2,3,
as well as migration of neuroblasts4, of differentiated neurons5
and of oligodendrocyte precursors6. Vice versa, neural cells
modulate CNS vascularization by either expressing pro-
angiogenic factors7–9 or by acting as support for vessel
formation and stabilization10.
The vertebrate CNS is initially avascular and becomes
vascularized by sprouting angiogenesis from a surrounding
vascular plexus. In the developing spinal cord (SC) blood vessels
sprout from the perineural vascular plexus (PNVP) and invade
the SC at the ventral side11,12. Simultaneously, neuronal
progenitor domains in the SC are being speciﬁed and organized
in a ventral to dorsal pattern, and post-mitotic neurons are
migrating towards their ﬁnal location in the SC13. One of
the best-characterized signals that controls CNS vascularization
is vascular endothelial growth factor (VEGF)8,12,14,15.
Neuroepithelium-derived VEGF controls the initial formation
of the PNVP and the invasion of vascular sprouts into the
neural tissue8,12. In addition, CNS vascularization is speciﬁcally
controlled by other angiogenic signals, such as Wnt7 or GPR124
(refs 16,17). For proper SC vascularization blood vessels do not
only need to sprout and grow but they also need to do it in a very
precise manner, by invading the SC at speciﬁc locations and by
following certain paths (stereotypical blood vessel patterning).
Yet, the identity of the neural cells, the spatial cues and the
signalling mechanisms that regulate this process remain largely
unknown. It is also unclear whether patterning cues modulate
VEGF signalling or act independently of the VEGF axis.
VEGF exerts its biological effects by interacting with two
tyrosine kinase receptors, VEGF receptor-1 (VEGFR1, also
known as fms-like tyrosine kinase, Flt1) and VEGF receptor-2
(VEGFR2, also known as fetal liver kinase, Flk1)18. Neuropilin-1
(NRP1), a receptor for class 3 Semaphorins, can also act as a
VEGF receptor or co-receptor19. While VEGFR2 is considered as
the main VEGF signalling receptor, Flt1 can either signal upon
VEGF binding or act as a VEGF trap20. Post-transcriptional or
post-translational modiﬁcations lead to a Flt1 isoform containing
the transmembrane and the intracellular domain (mFlt1), or to a
soluble isoform (sFlt1) lacking those two domains21. sFlt1 acts as
a VEGF sink to titrate the amount of VEGF available for
signalling22,23. In the endothelium, sFlt1, derived from the stalk
cells of a vessel sprout, regulates the response of that particular
sprout towards an external source of VEGF23,24. Whether a
sFlt1-dependent mechanism exists at the neuro-vascular interface
is unknown.
Gain-of-function studies in quail and chicken embryos showed
that VEGF expression is required for proper blood vessel
ingression into the SC12,25. Intriguingly, when blood vessel
sprouts invade the SC from the ventral side they avoid the ﬂoor
plate and the motor neurons (MNs), despite the fact that VEGF is
expressed in those areas26,27. These previous ﬁndings raise the
questions of what neuronal cell types are permissive for blood
vessel sprouting from the PNVP? When do MN columns become
vascularized in development? And how are VEGF expression and
signalling regulated by the neuronal compartment to control the
stereotypical blood vessel patterning in the SC? Here we have
revisited those initial ﬁndings and answered these questions.
We describe a neuro-vascular communication mechanism by
which MN columns prevent premature ingression of blood
vessels into their location. In an autocrine mechanism MNs
express VEGF to allow blood vessel growth, but at the same time
express sFlt1 to titrate the availability of VEGF in order to pattern
the vasculature and to block premature ingression of vessels into
MN columns during a developmental time window. This
‘attraction’ and ‘repulsion’ coming from the same cellular
source (here MNs) proposes a novel mechanism that uses
known angiogenic players to achieve proper tempo-spatial
vascularization of the CNS.
Results
Blood vessels grow in a stereotypical pattern in the SC.
To understand the process of SC vascularization during mouse
development in more detail, and to determine what neural
domains control blood vessel sprouting from the PNVP, we
analysed SC vascularization in correlation to different neuronal
populations of the developing SC at brachial and thoracic levels.
At E9.5 the PNVP (Isolectin-B4þ (IB4þ ) (ref. 16)) is already
formed but no blood vessels are invading the SC (Fig. 1a,b,f,j and
Supplementary Fig. 1a,e,i,m,u). Invasion of blood vessels starts at
around E10.0 and occurs ventrally, adjacent to the ﬂoor plate and
lateral to MN columns. Subsequently, blood vessels, without
invading the ﬂoor plate (Supplementary Fig. 1b–d), elongate
through V3 post-mitotic interneurons (Sim1þ ) (Supplementary
Fig. 1f–h) and in close contact with the p3 (Nkx2.2þ , neuronal
progenitor domain generating V3 interneurons) and the pMN
(Olig2þ , neuronal progenitor domain generating MNs) domains
(Supplementary Fig. 1j–l,n–t). Starting at E10.5, ventral blood
vessels surround MN columns (Isl1/2þ ) without invading them,
while new blood vessels invade and branch in the dorsal SC
(Fig. 1a,c,g) but avoid the most dorsolateral areas (Supplementary
Fig. 1u–w). While MN columns remain still avascular at E11.5
(Fig. 1a,d,h), at E12.5 blood vessels can be detected (Fig. 1a,e,i).
Similar vascularization pattern was also observed at other levels of
the SC (Supplementary Fig. 1y-b’). Altogether, these results
suggest that the ventral domains of ﬂoor plate, p3, V3 inter-
neurons, pMN and MNs might control the initial steps of SC
vascularization and patterning, with V3 interneurons, p3 and
pMN neuronal domains acting as ‘vascular attractant’ sites,
whereas ﬂoor plate and MNs acting as ‘repellent’ sites.
VEGF is dynamically expressed during SC vascularization.
SC-derived VEGF is known to control CNS vascularization8,12,25.
However, a precise characterization of the spatial and temporal
VEGF expression, and the identity of the different neuronal
populations expressing VEGF are lacking or fragmentary. Thus,
we correlated the process of SC vascularization with VEGF
expression and identiﬁed the cellular sources of VEGF. In situ
hybridization (ISH) for Vegf combined with IB4 staining showed
that Vegf expression changes dynamically during the process of
SC vascularization. At E9.5 when the PNVP is formed, Vegf is
uniformly expressed in the entire SC (Fig. 1j). At later
developmental stages its expression in the ventral SC increases
and becomes restricted to speciﬁc neuronal progenitor
domains and groups of differentiated neurons, coinciding with
ingression of blood vessel sprouts from the PNVP into the SC
(E10.5), elongation and branching (E10.5-E12.5) (Fig. 1k–m).
A combination of ISH with immunostaining for the MN marker
Isl1/2 or for the p3 neuronal domain marker Nkx2.2 showed that
at E10.5 and E11.5 Vegf is highly expressed in MN columns
(Fig. 1o,p), in the ﬂoor plate (Fig. 1s,t) and in the neuronal
progenitor zone (Fig. 1k–m,o–q,s–u). At E12.5, the time when
MN columns become vascularized, Vegf expression is still present
in MN columns (Fig. 1q). These results are consistent with
previously described Vegf expression in the mouse and quail
SC8,12,25,27, and in addition identify the ventral neuronal
populations acting as sources for Vegf.
Our correlative analysis of Vegf expression and SC vasculariza-
tion (Fig. 1j–m) conﬁrms that MN columns, expressing Vegf, are
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not invaded by blood vessels despite the fact that VEGF is a
potent vascular attractant (Fig. 1k,l). It suggests that during a
developmental time window sprouting blood vessels are ‘blind’ to
MN-derived VEGF and that perhaps VEGF signalling in these
sprouting vessels is counteracted by other, yet unidentiﬁed,
molecular mechanisms. These counteracting mechanisms should
be released at later developmental stages (E12.5) when blood
vessels enter MN columns still expressing VEGF.
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Figure 1 | Blood vessel sprouts invade the developing mouse spinal cord at speciﬁc locations and grow in a stereotypical pattern. (a) Scheme of SC
vascularization during mouse development (E9.5 till E12.5), showing blood vessels (BV, red), the ﬂoor plate (FP, orange) and the MN columns (green).
(b–e) Representative images of SCs at the developmental stages indicated, showing labelled endothelial cells (IB4þ ) and post-mitotic MNs (Isl1/2þ ).
(f–i) Higher magniﬁcations of insets in b–e. Note blood vessels stay outside the Isl1/2þ domain till E12.5. (j–m) Representative images of blood vessel
staining (IB4þ ) in the SC combined with ISH for Vegf from E9.5 till E12.5 in mice. At E9.5 (j), Vegf is uniformly expressed in the entire SC (white arrowhead:
PNVP). From E10.5 till E12.5 (k–m) Vegf expression becomes restricted to speciﬁc neuronal domains (yellow dotted lines: MN columns; orange arrowheads:
FP; blue arrowhead: neuronal progenitors). (n–q) Representative images of ISH for Vegf combined with immunostaining for MNs (Isl1/2þ ) conﬁrming
that Vegf expression is highly localized and increased in MN columns from E10.5 onwards. Insets show higher magniﬁcations of MN columns.
(r–u) Representative images of ISH for Vegf combined with immunostaining for the p3 neuronal progenitor domain (Nkx2.2þ ) revealing expression of Vegf
in the p3 domain and in the FP (orange arrowheads: FP (domain Nkx2.2 , below Nkx2.2þ )). Insets show higher magniﬁcations of the FP region (white
dotted outlines: FP). Scale bars 100 mm.
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VEGF expression is regulated by HIF1a. In an attempt to
identify potential mechanisms that could regulate VEGF expres-
sion at the MN level we performed an in silico analysis. We ﬁrst
used Cytoscape (an open source software to analyse biomolecular
network interactions28) to generate a list of potential VEGF
regulators (Supplementary Data 1), which we then ﬁltered by
presenting it to an already available gene expression data set of
SC MNs at E11.5 (ref. 29) (Supplementary Data 2). Enrichment
analysis for signalling pathways of the obtained list of genes
(using the Enrichr web-based software30) indicated that the
response to hypoxia, and in particular HIF1a was highly enriched
in MNs at E11.5 (Supplementary Fig. 2a,b). As HIF1a is a
well-known regulator of VEGF expression31 we investigated
whether it regulates VEGF expression in SC MNs.
In fact, HIF1a expression and nuclear localization at MN
columns correlated with VEGF expression during development.
At E10.5 HIF1a was present in MNs and partly localized in the
nucleus (Fig. 2a,d,g). While at E11.5 HIF1a was mainly localized
in the nucleus of MNs (Fig. 2b,e,h), by E12.5 its expression
pattern became partially excluded from the nucleus (Fig. 2c,f,i),
consistent with higher oxygen levels due to the presence of
blood vessels. Expression of carbonic anhydrase IX (CAIX),
another HIF1a target gene, correlated with HIF1a expression
in MN columns (Supplementary Fig. 2c–k). Moreover, mRNA
expression of prototypical HIF target genes in microdissected MN
columns correlated with HIF1a expression pattern (Supplementary
Fig. 2l–n).
One of the major regulators of HIF1a function, and therefore
of Vegf expression, is hypoxia31. Indeed, culture of isolated MN
column explants from E11.5 mouse SCs in hypoxic conditions
resulted in increased levels of Vegf as well as other HIF1a target
genes (Fig. 2j–m). This increase of Vegf levels was HIF1a
dependent as the addition of chetomin (a small molecule that
attenuates HIF1a-dependent transcription32) abolished it (Fig. 2j–m).
Since SC vascularization and Vegf expression in chicken
embryos are similar to mouse (Supplementary Fig. 3)33, and
HIF1a is expressed in MNs of chicken SCs34, we used chicken
embryos to conﬁrm that Vegf expression is regulated by HIF1a
in vivo. For this, we injected chetomin into the SC canal of
chicken embryos. Analysis of Vegf expression revealed a strong
decrease in Vegf levels in MN columns in the presence of the
HIF1a inhibitor (Fig. 2n,o). The expression of Vegf in neuronal
progenitors and ﬂoor plate was not completely abolished,
indicating that the inhibition of HIF1a-dependent transcription
was not completely blocked in these cells, or that Vegf expression
is also regulated in a HIF1a-independent manner.
VEGF overexpression results in premature MN vascularization.
If a balance between VEGF and inhibitory cues is needed to
control the speciﬁc vascular patterning of the ventral SC, a
deregulation of this balance towards higher concentrations of
VEGF might result in premature invasion of blood vessels into
the restricted areas. To speciﬁcally overexpress VEGF in the
embryonic ventral SC at the time of SC vascularization, we used
the transgenic mouse line (TgN(NSEVEGF)1651 (V1)), named
from here on NSE-VEGFtg. These mice express the human
VEGF165 isoform under the promoter of the neuron-speciﬁc
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Figure 2 | VEGF expression is regulated by HIF1a. (a–c) Representative images of SCs at the developmental stages indicated, showing HIF1a staining in
post-mitotic MNs (Isl1/2þ ). (d–i) Higher magniﬁcations of insets in a–c showing co-localization of HIF1a and Isl1/2þ (d–f) or just HIF1a staining (g–i).
Note the changes of HIF1a nuclear localization during development. (j–m) qRT-PCR analysis of changes in expression levels of Vegf (j) and other
prototypical HIF target genes (Bnip3 (k), Pdk1 (l) and Egln3 (m)), when explants from mouse E11.5 MN columns are cultured under normoxia (20% O2)
(green bars) or hypoxia conditions (1% O2) (red bars), with or without chetomin. Data are represented as mean±s.e.m. n¼ 2 individual experiments done
in triplicates. (j) *P¼0.0161, **P¼0.0086 (normoxia versus hypoxia), **P¼0.0082 (hypoxia versus hypoxiaþ chetomin); (k) *P¼0.0169, **P¼0.0056
(normoxia versus hypoxia), **P¼0.0018 (hypoxia versus hypoxiaþ chetomin); (l) ***P¼0.0007, ****Po0.0001; (m) ****Po0.0001. One-way ANOVA
using Tukey’s multiple comparisons test was performed for (j–m) and P Values were adjusted to account for multiple comparisons. (n,o) Representative
images of ISH for Vegf mRNA in chicken embryos (HH27) treated either with control (DMSO) (n) or with chetomin (o). Note the absence of Vegf
expression in MN columns of the chetomin-treated embryo (black dotted lines: MN columns). Scale bars 100mm. ANOVA, analysis of variance.
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enolase (NSE)35 and its expression can be detected in SCs of
E11.5 embryos (Supplementary Fig. 4a). Consistent with the
Nse expression pattern (Supplementary Fig. 4b–e), hVegf165 is
much higher expressed in microdissected MN columns than in
the dorsal SC of E11.5 NSE-VEGFtg embryos (Supplementary
Fig. 4f). ISH for Vegf using a probe that detects both mVegf and
hVegf also revealed that NSE-VEGFtg mice expressed higher
levels of Vegf (mVegfþ hVegf) in the ventral SC, in particular in
MN columns, when compared with WT embryos (Supplementary
Fig. 4g,h).
E9.5 WT and NSE-VEGFtg embryos showed no anatomical
differences and no blood vessel sprouts inside the SC
(Supplementary Fig. 5a–c). At E10.5 and E11.5, NSE-VEGFtg
embryos displayed similar sizes and anatomical features as WT
embryos (Supplementary Fig. 5c) but showed small haemorrhages
in the brain and in the SC (Supplementary Fig. 5d–g).
Quantiﬁcation of blood vessel density in the entire SC revealed
B1.5-fold increase in NSE-VEGFtg embryos compared with WT
embryos at E10.5 (Fig. 3a,c,i) and E11.5 (Fig. 3e,g,k).
Furthermore, detailed analysis of MN columns also showed
a strong increase in blood vessel density in NSE-VEGFtg
embryos (Fig. 3b,d,f,h,j,l). Comparable vascularization defects
were observed at brachial and thoracic levels (Supplementary
Fig. 5h–p).
To analyse blood vessel guidance, we determined the ingression
pattern of blood vessels into the SC, focusing in particular on MN
columns, where hVEGF165 is highly expressed. Angles of
angiogenic sprouts ingressing into the ventral half (0–90) were
calculated as previously described12 (Supplementary Fig. 5q). As
expected, in WT embryos, blood vessel ingression into the SC
occurred in a highly stereotypical pattern with very few sprouts
entering through MN columns (between 20–55, Supplementary
Fig. 5q) (Fig. 3m–o). Remarkably, in NSE-VEGFtg embryos blood
vessels ingressed signiﬁcantly more often through the MN
columns (Fig. 3m–o) while the ﬂoor plate remained avascular
as in WT embryos (Supplementary Fig. 5r,s).
Finally, we questioned whether the observed premature
ingression of blood vessels into MN columns would have
any consequences in MN development. Analysis of total number
of all MNs (Islet1/2þ ) or of lateral MNs (FoxP1þ , Islet1/2þ )
revealed no differences between WT and NSE-VEGFtg
embryos (Supplementary Fig. 6a–f). However, analysis of the
distribution of all MNs or of lateral MNs showed that MNs were
positioned abnormally and intermixed in NSE-VEGFtg embryos
(Supplementary Fig. 6g–t). In addition, evaluation of motor axons
exiting the SC showed that while in WT embryos axons leave the
SC in a fasciculated manner, in NSE-VEGFtg these were highly
defasciculated (Supplementary Fig. 6u–x).
Collectively, these results indicate that an increased, thus
unbalanced, expression of VEGF in the ventral SC is sufﬁcient to
deregulate ventral vascular patterning. Although we cannot
exclude a direct effect of the overexpressed VEGF on MNs, these
data indicate that in the presence of blood vessels MNs do not
cluster properly and suggest that MN columns should remain
avascular until E12.5 to assure their proper grouping and
positioning within columns. Furthermore, they also support a
model where inhibitory signals in MN columns can be overcome
by VEGF overexpression.
MN conditioned medium has a pro-angiogenic effect. To
investigate whether MN columns might express inhibitory factors
that prevent blood vessel ingression, and whether these are
long-range or short-range cues, we performed several in vitro
approaches with isolated MN explants from E11.5 WT SCs
(Supplementary Fig. 7a). To test whether MNs secrete inhibitory
cues, we obtained conditioned medium (CM) from MN explants
and tested its angiogenic potential on human brain microvascular
endothelial cells (HBMECs36). First, we analysed HBMEC
migration using a transwell assay and found that in contrast to
an inhibitory angiogenic effect, HBMECs migrated signiﬁcantly
more in the presence of MN-CM than in control conditions
(Fig. 4a). Recombinant VEGF was used as a positive control
(Supplementary Fig. 7b). Next, we performed a matrigel-based
tube formation angiogenic assay37. Consistently, when HBMECs
were treated with MN-CM, an increase in tube length and tube
branching was observed (Fig. 4b,d,f,g). We then compared the
effect of MN-CM with the CM from explants of the area dorsally
adjacent to MN columns, which is permissive to blood vessels,
and which we termed ingression site (immunostaining for MN or
interneuron markers conﬁrmed the nature of the explants
(Supplementary Fig. 7c–f)). Quantiﬁcation of tube length and
branching showed that MN-CM has similar pro-angiogenic
effects as the CM from ingression site explants (Supplementary
Fig. 7g,i,k,l).
Since VEGF is present in MN-CM (Supplementary Fig. 7m) we
tested whether the observed pro-angiogenic effect can be reversed
by the addition of recombinant Flt1/Fc22, which traps VEGF.
Indeed, Flt1/Fc blocked the pro-angiogenic effects observed in
the transwell and in the tube formation assay (Fig. 4a,c,e–g).
Interestingly, Flt1/Fc could not block the pro-angiogenic effects of
ingression site-CM (Supplementary Fig. 7b,h,j–l), suggesting that
VEGF is not the sole pro-angiogenic factor in this SC region and
that perhaps other factors (i.e., Wnt7a/b) might be responsible for
the angiogenic effect.
These results indicate that MN columns secrete VEGF, which
is pro-angiogenic. They further suggest that inhibition of blood
vessel invasion into MN columns might be then mediated by a
short-range, locally expressed and retained, inhibitory cue.
MNs express short-range anti-angiogenic factors. To explore
the possibility that a short-range inhibitory cue is responsible for
preventing blood vessels from invading MN columns, we devel-
oped two neuro-angiogenic assays (Supplementary Fig. 7a). First,
we tested the probability of HBMEC tubes to approach a MN
explant by co-culturing them on matrigel (Supplementary
Fig. 7a). Time lapse imaging, as well as quantiﬁcation of images
taken at the end of the experiment, showed that while HBMECs
formed tubes and remained attached to ingression site explants,
in the presence of MN explants tubes formed at a distance from
the explant and very few touched them (Fig. 4h–j, Supplementary
Movie 1 and 2). Explant size was similar in all experimental
conditions (Supplementary Fig. 7n).
Second, we tested the capacity of HBMECs to migrate towards
a MN explant. For this, we modiﬁed the traditional scratch
assay37 by placing the explant in the scratch area. At 6 h after the
initiation of the assay no difference was observed when
comparing the migration of HBMECs alone or in the presence
of ingression site or MN explants (Fig. 4n). After 20 h, HBMECs
cultured alone or in the presence of ingression explants had
closed or almost closed the gap, respectively (Fig. 4k,m,n).
However, HBMECs in the presence of MN explants had only
covered 88% of the gap by then (Fig. 4l,n). By 30 h, this effect
was still observed (Fig. 4n). We also used MN explants from
NSE-VEGFtg mouse embryos or their WT littermates (explant
size was similar for both genotypes, Supplementary Fig. 7o).
While no differences were observed at 6 h (Fig. 4q), at 20 h and
30 h HBMECs in the presence of NSE-VEGFtg-MN explants had
closed the gap signiﬁcantly more than HBMECs in the presence
of WT-MN explants (Fig. 4o–q). This result further supports our
hypothesis that VEGF overexpression is able to overcome the
potential inhibitory cues present in MNs.
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Together, these data suggest that MNs express a membrane-
bound or a poorly diffusible factor, potentially associated with the
extracellular matrix (ECM), that is capable of patterning the
vasculature within a short radius of action. Thus, vessels would be
allowed to grow around MN columns but would be prevented
from invading them. Moreover, our results suggest that a tightly
controlled balance between this inhibitory factor(s) and VEGF is
required for proper blood vessel patterning.
mFlt1 and sFlt1 are expressed in MN columns. Since sFlt1 and
mFlt1 have an effect on vascular patterning by acting as negative
angiogenic regulators via VEGF trapping20,22, and sFlt1 remains
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angle for the different ingressing sprouts. (o) Quantitative analysis of blood vessel ingression angles into the ventral half (0–90) of E11.5 SCs. Note that in
NSE-VEGFtg embryos blood vessels ingress signiﬁcantly more often through the MN columns (20–55) compared with WT littermates. n¼ 11 WT
embryos and n¼ 24 NSE-VEGFtg embryos from six different litters. **P¼0.0038 (20–55), **P¼0.0080 (55–90). Data are represented as
mean±s.e.m. Scale bars 100mm.
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matrix-associated38,39, we hypothesized that they could be
putative candidates for counteracting VEGF derived from MN
columns and thus for controlling SC vascularization patterning.
Using an anti-Flt1 antibody that recognizes the extracellular
domain, and thus detects mFlt1 and sFlt1 (mFlt1þ sFlt1 is
from here on termed Flt1)40, we found Flt1 in blood vessels
(Fig. 5a,b,e,f,i,j), radial glia (Fig. 5c,d) and highly expressed in
MN columns, both at E10.5 and at E11.5 (Fig. 5a–h). However,
by E12.5 Flt1 expression was reduced in MN columns and
became more homogeneous within the SC (Fig. 5i–l). We next
determined the mRNA expression pattern of each isoform using
RNAscope probes designed to detect either mFlt1 or sFlt1
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mean±s.e.m. Scale bars 100mm. ANOVA, analysis of variance.
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speciﬁcally. Consistent with our immunohistochemistry data,
we detected expression of both isoforms in blood vessels and in
MNs, which was markedly decreased in MNs at E12.5 (Fig. 5m–p;
Supplementary Fig. 8a,b).
Having conﬁrmed the expression of sFlt1 in MNs, we next
determined whether it is indeed secreted by MNs but associated
to the ECM. ELISA analysis revealed that treatment of MN
explants with heparin treatment (known to induce the release of
IB4 Flt1
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Figure 5 | mFlt1 and sFlt1 are expressed in MN columns. (a,b,e,f,i,j) Representative images of immunostaining for Flt1 (mFlt1þ sFlt1) combined with blood
vessel staining (IB4þ ) at E10.5 (a,b), E11.5 (e,f) and E12.5 (i,j). (c,d,g,h,k,l). Representative images of immunostaining for Flt1 (mFlt1þ sFlt1) and for Isl1/
2þ (post-mitotic MNs) at E10.5 (c,d), E11.5 (g,h) and E12.5 (k,l). Note Flt1 can be detected in blood vessels (white arrowheads), radial glia (blue
arrowheads, identiﬁed by its typical morphology), as well as in MN columns (yellow dotted outlines). (m–p) Representative images of RNAscope Multiplex
Fluorescent Assay using speciﬁc probes to detect mFlt1 and sFlt1 combined with staining for nuclei (DAPIþ ) and either staining for blood vessels (IB4þ )
(m,o) or immunostaining for MNs (Isl1/2þ ) (n,p) at E11.5 (m,n) and E12.5 (o,p). Scale bars 100mm. Right panels: higher magniﬁcations of insets. Scale bars
of insets 10mm.
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ECM-retained sFlt141) signiﬁcantly increased the amount of sFlt1
present in MN-CM (Supplementary Fig. 8c). Consistent with the
release to the medium, quantiﬁcation of Flt1 (mFlt1þ sFlt1) in
the corresponding lysates of MN explants revealed a signiﬁcant
reduction of Flt1 in heparin-treated explants (Supplementary
Fig. 8d).
These results support a model in which mFlt1 and/or sFlt1 can
locally counteract VEGF-signalling by trapping VEGF, and thus
regulate SC vascularization. Moreover, at E12.5 Flt1 expression
becomes lower in MN columns. This change in expression
pattern correlates with the invasion of blood vessel sprouts into
MN columns at E12.5 and suggest that the VEGF-trapping action
might be released by then.
MN-speciﬁc loss of sFlt1 leads to premature vascularization.
To determine whether mFlt1 and/or sFlt1 prevent premature
vascularization of MN columns, we applied in ovo RNAi
electroporation in a cell-type speciﬁc manner. We used the
MN-speciﬁc Hb9 promoter (Hb9p2.5distal/M-250-TATA42,43) to
drive the expression of artiﬁcial microRNAs (miRNA) in MNs.
The targeting vector also encoded EGFP to identify the
electroporated MNs in the chicken SC (Supplementary
Fig. 9a,b). Chicken SC vascularization starts at developmental
stages HH17/19. By HH26/27 blood vessels surround
MN columns and by HH30 blood vessels start invading them
(Supplementary Fig. 3). Therefore, we unilaterally electroporated
the SC at HH17 and analysed SC vascularization at HH29, using
the non-electroporated side as internal control. In all conditions
around 55% of Isl1/2þ were targeted.
In control conditions (Hb9-EGFP-miLuc) chicken embryos
displayed a normal vascular phenotype (Supplementary Fig. 9c–e).
In contrast, when Flt1 (mFlt1þ sFlt1) was knockdowned using an
artiﬁcial miRNA for Flt1 (Hb9-EGFP-miFlt1#1) (Fig. 6b and
Supplementary Fig. 9f,g), blood vessel density in MN columns of
the electroporated side was 2.5-fold increased compared with the
non-electroporated (control) side (Fig. 6a,c). Analysis of blood
vessel patterning upon Flt1 knockdown showed more vessel
sprouts ingressing through MN columns as in the control side
(20–80 angles, Fig. 6d). No difference in vessel patterning was
observed in other regions of the ventral SC (Supplementary
Fig. 9h). To determine whether sFlt1 was speciﬁcally required for
preventing ingression of blood vessels into MN columns, we used
an artiﬁcial miRNA targeting just sFlt1 (Fig. 6f; Supplementary
Fig. 9i). The sole knockdown of sFlt1 resulted in an increase in
blood vessel density in the electroporated MN column compared
with the control non-electroporated side (Fig. 6e,g). Blood vessel
patterning was also affected as vessel sprouts ingressed sig-
niﬁcantly more often through the MN columns (Fig. 6h), but not
through other regions of the SC (Supplementary Fig. 9j). Similar
results were obtained with a second set of artiﬁcial miRNA-based
vectors targeting a different coding sequence of either Flt1
or sFlt1 (Supplementary Fig. 9k–n). We then performed a
rescue experiment by co-electroporating an Hb9-driven plasmid
encoding mouse sFlt1 together with the Hb9-EGFP-misFlt1#1.
Analysis of blood vessel density showed that the premature blood
vessel ingression caused by Hb9-EGFP-misFlt1#1 was rescued
(Fig. 6i–l), demonstrating the speciﬁcity of the miRNA used.
As we observed that the expression of Flt1 in MNs decreased at
developmental stages when blood vessels start invading MN
columns (Fig. 5), we asked whether maintained expression of
sFlt1 in MNs would prevent blood vessels from entering these
areas. For this, we electroporated the Hb9-sFlt1-HA plasmid in
the embryonic chicken SC and analysed MN vascularization at
HH30, when blood vessels have already naturally invaded MN
columns (Supplementary Fig. 3f,l,r,x). Quantiﬁcation showed that
while in the non-electroporated side blood vessels were already
present in MN columns, in the sFlt1 overexpressing MN columns
still very few vessels were detected (Fig. 6m–o).
Collectively, these experiments demonstrate that the pro-
angiogenic effect of MN-derived VEGF is counteracted by the
inhibitory effect of sFlt1 expressed by MNs. They show that sFlt1
levels need to be tightly regulated, as a partial reduction of sFlt1
is already sufﬁcient to cause miss-guidance of blood vessel
sprouts and premature MN column vascularization. Moreover,
maintained expression of sFlt1 in MNs prevents blood vessel
ingression at developmental stages when they normally start
invading MN columns.
Neuropilin-1 regulates sFlt1 expression in MNs. To understand
how sFlt1 is regulated in MNs, we screened for potential
regulators of Flt1 expression or function in MNs using the same
in silico approach as the one described above (Supplementary
Data 3 and 4). Analysis of the generated list of genes
(Supplementary Data 4) for enriched pathways revealed as top
hits many of the known molecules involved in Flt1 functional
regulation and signalling (Supplementary Fig. 10a,b).
We selected Neuropilin-1 (NRP1) for further analysis as we
observed that its expression pattern in MN columns correlates
with Flt1 expression. Indeed, Nrp1 is highly expressed in MNs
from E9.5 till E11.5 and decreases at E12.5 (Fig. 7a–e). Also, its
expression pattern changes from being uniformly expressed
within MN columns at E9.5-E10.5 to become restricted to
speciﬁc MN subpopulations at E11.5-E12.5 (Fig. 7a–d). A similar
expression pattern was observed in chicken embryos (Fig. 7f–k).
To explore whether NRP1 expression had any role on sFlt1
regulation in MNs, we silenced NRP1 in chicken embryo MNs
using two different Hb9-driven artiﬁcial miRNA constructs
(Fig. 7l; Supplementary Fig. 10c). Downregulation of Nrp1 in
MNs led to decreased mFlt1 and sFlt1 mRNA levels, without
changing Vegf expression levels (Fig. 7l; Supplementary Fig. 10c),
indicating that NRP1 transcriptionally regulates Flt1, and thus
shifts the balance towards higher VEGF availability. The same
vascular phenotype observed upon decreased sFlt1 levels was also
observed upon NRP1 downregulation (Fig. 7m,n; Supplementary
Fig. 10d). Thus, to determine whether this vascular phenotype
was due to the decreased sFlt1 levels, we co-electroporated the
NRP1 miRNA containing plasmid together with the Hb9-mouse
sFlt1-HA plasmid. Co-expression of mouse sFlt1 rescued the
phenotype induced by NRP1 knockdown (Fig. 7o,p), demonstrat-
ing that MNs control vascular patterning by a mechanism that
depends on the transcriptional regulation of sFlt1 by NRP1.
Discussion
In the developing SC a variety of different processes has to be
orchestrated in a precise temporally controlled manner. At the
same time as neurons in the SC migrate and form networks,
blood vessels invade the SC. To guarantee proper adaptation
and synchrony with the neuronal environment, blood vessel
formation, invasion and guidance within the SC needs to be
highly controlled. In this study we report a novel mechanism by
which MNs control blood vessel patterning in the developing SC
in a tempo-spatial regulated manner (Fig. 8).
After the PNVP is formed, blood vessels sprout from the PNVP
and invade the SC7,12,16. Once inside, blood vessels also pattern in
a stereotypical manner. Due to the different binding afﬁnities
to the extracellular matrix, VEGF isoforms act as long-range
and short-range vessel patterning cues and locally guide vessel
sprouts in the CNS44. However, a single unifying model of blood
vessel patterning solely controlled by VEGF cannot explain SC
vascularization. In fact, our correlated analysis of Vegf expression
with the patterning of blood vessels in the SC revealed that,
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vessel density in MN columns (Isl1/2þ ) shown as ratio between electroporated side and non-electroporated one. n¼ 8, **P¼0.0012 for (c) and n¼ 8,
*P¼0.0366 for (g). (d,h) Quantiﬁcation of the angle of ingression showing a signiﬁcant increase in blood vessel sprouts ingressing into MN columns in the
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(j) qRT-PCR analysis conﬁrms downregulation of chicken sFlt1 levels in MN columns in the electroporated side. n¼6, ****Po0.0001. (k) qRT-PCR analysis
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despite the high expression levels of Vegf in MN columns at
E10.5-E11.5, blood vessels do not invade those regions until E12.5
(or until HH30 in chicken). To explain this highly regulated
and stereotypical blood vessel patterning, here we favour the
model where negative vascular cues also participate in SC
vascularization. Indeed, our data showed that MN columns
express both, long-range pro-angiogenic factors (secreted) as well
as short-range inhibitory cues, which together balance the blood
vessel response (Fig. 8).
Proper development of the vasculature requires a tightly
controlled regulation of VEGF levels, as just a slight reduction
or increase of VEGF results in severe vascular defects14,45.
NSE-VEGFtg embryos, which overexpress hVEGF165 in MNs,
have altered SC vascularization with premature blood vessel
invasion of MN columns (Fig. 8), suggesting that VEGF
availability around MN columns needs to be tightly regulated
and that potential local counteracting/inhibitory cues should
ensure this effect. Here, we identiﬁed sFlt1 as one of these
inhibitory cues. Indeed, sFlt1 is expressed and locally retained
at MNs, and its MN-speciﬁc knockdown leads to premature
ingression of blood vessels into MN columns (Fig. 8). At the
developmental stage when blood vessels normally invade MN
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columns sFlt1 expression is lower than at earlier stages,
suggesting that a reduction of sFlt1 releases the brake and
allows vessel ingression by freeing higher amounts of VEGF.
The tight regulation of VEGF availability in MNs is further
demonstrated by the fact that a partial reduction of sFlt1 is
sufﬁcient to allow blood vessel invasion in MN columns.
Different molecular pathways are known to regulate Flt1
expression and function24,46. Here we show that NRP1 expressed
in MNs regulates Flt1 (mFlt1 and sFlt1) at a transcriptional level
and that knockdown of NRP1 results in premature ingression of
blood vessels into MN columns (Fig. 8), which can be rescued by
re-expression of sFlt1. During development NRP1 is required for
proper positioning of MN somata within the SC47, motor axon
growth, guidance and fasciculation48–51. For these functions,
NRP1 signalling in MNs is activated by Sema3A48,49,51. Our study
shows a new role for MN-derived NRP1 as an indirect regulator
of blood vessel patterning (Fig. 8) and positions NRP1 as a
coordinator of neuro- and vascular patterning from the MN side.
Future studies will elucidate the ligand that activates NRP1 in
MNs to control sFlt1 expression.
Several studies have implicated endothelial-derived sFlt1 as a
patterning factor that inactivates VEGF in vascular regions very
close (from cell to cell) to the vessel sprout23,24,52. Expression of
sFlt1 in the cornea also assures cornea avascularity22. Here we
show that sFlt1 is expressed in both, blood vessels and MNs.
Although we cannot exclude the possibility that endothelial-
derived sFlt1 is also regulating vessel patterning along MN
columns, the MN-speciﬁc deletion of sFlt1 indicated that its
presence in MNs is crucial for proper SC vascularization.
Therefore, a model where vessel- and MN-derived sFlt1
controls VEGF availability at both sides of the growing vessel is
very likely to exist. Interestingly, sFlt1 is not the only VEGF
receptor described to titrate VEGF levels in the CNS. In the
developing retina, retinal neurons express VEGFR2 that traps
VEGF via endocytosis and hence controls the direction of newly
formed vessel sprouts53. Thus, different neurons use different
VEGF receptor-mediated mechanisms to titrate VEGF.
Our ﬁndings raise two questions. First, why do blood vessels
remain outside MN columns for a speciﬁc developmental
window? During E9.5 till E12.5 differentiated MNs are migrating
into MN columns, MN cell bodies are clustering into columns,
are establishing synaptic contacts and are extending their axons
out of the SC to innervate speciﬁc muscles54. Thus, the presence
of vascular sprouts could interfere in these processes. We
speculate that MNs developed a mechanism to prevent that this
happens and to allow vascularization when those processes are
assured. In support of this, in NSE-VEGFtg embryos, where blood
vessels invade MN columns prematurely, a MN clustering and
axon fasciculation defect was observed. And second, why would a
system express a ligand (VEGF) that then needs to be inactivated
(via sFlt1)? We propose that sFlt1 traps the required amount of
VEGF within MN columns in order to block premature blood
vessel ingression, but that still certain levels of VEGF remain
available, and are required to control endothelial cell survival,
proliferation and growth of vessels surrounding the columns.
In summary, we show that VEGF signalling needs to be tightly
regulated in order to guarantee proper blood vessel patterning in
the developing SC. We demonstrate that MNs guide blood vessels
by reusing classical angiogenic molecules in an alternative way.
They present an autocrine mechanism by which they produce
VEGF but at the same time themselves regulate VEGF availability
by their own expression of sFlt1. Our work provides new insights
into the regulatory mechanisms that control CNS vascularization,
which could be relevant in understanding and designing new
treatment strategies for different CNS pathologies.
Methods
Animals. All experimental protocols, handling use and care of mice were approved
by the local authorities and animal welfare ofﬁcers and in accordance with the NIH
‘Guide for the Care and Use of Laboratory Animals’. The TgN(NSEVEGF)1651
Normal
VEGF gain-of-function
or
sFlt1 loss-of-function
or
NRP1 loss-of-function
Blood vessel
ingression
MN column
at E11.5
NRP1
VEGF sFlt1
VEGF
sFlt1
No blood vessel
ingression
Figure 8 | Model of how MNs control blood vessel patterning in the developing SC. MNs express VEGF to allow blood vessel growth, but at the
same time express sFlt1 to titrate the availability of their own produced VEGF in order to pattern the vasculature and prevent premature ingression of
vessels into MN columns during a developmental time window. sFlt1 expression is transcriptionally regulated by NRP1. A deregulation of the balance
towards higher concentrations of VEGF (VEGF gain-of-function, sFlt1 loss-of-function, or NRP1 loss-of-function (thus reduction of sFlt1)) results in the
premature invasion of blood vessels into MN columns, indicating that VEGF levels need to be tightly titrated.
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(V1) mouse line was previously described35,55. Wild-type littermates (WT) were
used as controls. WT CD1 and C57Bl/6 mice were purchased from Janvier Labs
and Charles Rivers.
All experiments involving chicken embryos were carried out according to the
guidelines of the Cantonal Veterinary Ofﬁce Zurich (Switzerland) as well as in
accordance to local authorities and animal welfare ofﬁcers of Baden-Wuerttemberg
(Germany).
Generation of miRNA constructs. Constructs encoding miRNAs were generated
as described43. Brieﬂy, the mouse Hoxa1 enhancer III and minimal TATA box
promoter from Hox-EGFP SDM in pBSKþ vector was replaced by Hb9p2.5distal/
M-250-TATA box promoter. As negative controls, miRNA against ﬁreﬂy
Luciferase (Hb9-EGFP-miLuc) was used. See Supplementary Table 1 for a complete
list of miRNAs used in this study.
Generation of Hb9-sFlt1-HA plasmid. peak12-Hb9p25distal/M-250-TATA-
EGFP was digested with HindIII and NotI. The mouse sFlt1 insert was ampliﬁed
from mouse cDNA using speciﬁc primers with 3xHA-extension. The PCR products
were digested with HindIII and NotI. Vector and insert were ligated following the
manufactures instructions (NEB T4 DNA Ligase). The resulting plasmid was
named Hb9-sFlt1-HA. See Supplementary Table 2 for primer sequences used.
In ovo RNAi electroporation and blood vessel analysis. In ovo RNAi was
performed as described56. Brieﬂy, chicken embryos (HH17) were injected with
miRNA (800 ng ml 1) into the central canal of the SC and electroporated
subsequently (ﬁve pulses of 50ms duration at 18V). Eggs were placed back into a
38.5 C incubator until HH29 or HH30 when SC vascularization was analysed.
A control b-actin-RFP construct was co-electroporated as a positive control to
assure that the electroporation worked43. For rescue experiments miRNA
constructs (800 ng ml 1) were co-electroporated with Hb9-sFlt1-HA
(500 ng ml 1). Mouse sFlt1-HA was not sensitive to misFlt1#1 (speciﬁc for
chicken). Speciﬁcity was quantiﬁed by quantitative real-time PCR (qRT-PCR)
analysis. For experiments, SC vascularization after electroporation was analysed by
ISH for Vegfr2 (expressed in endothelial cells in chicken25) combined with
immunostaining for the MN marker Isl1/2.
In ovo injection of Hif1-a inhibitor. All stock solutions were prepared in DMSO.
Either control (DMSO-solvent) or chetomin (C9623, Sigma-Aldrich) (1mg kg 1)
was injected into the SC canal of chicken embryos at stage HH24, and injections
were repeated every 8 h till embryo dissection and subsequent analysis at HH27.
RNAscope multiplex ﬂuorescent assay. mFlt1 and sFlt1 RNAscope probes were
designed to detect either mFlt1 (C1 Mm-Flt-O1 443931) or sFlt1 (C2 Mm-Flt1-O2-
C2 443941) in mice. RNAscope Multiplex Fluorescent Assay on ﬁxed frozen tissue
sections was performed according to manufacturer’s instructions (Advanced Cell
Diagnostics). Subsequently, blood vessels and MNs were visualized using Isolectin
GS-IB4 Alexa Fluor 568 conjugate (1:250, Invitrogen) for 2 h at room temperature
(RT) or Isl1/2 (1:200, DSHB) 4 C overnight, respectively. As negative control a
RNAscope probe detecting dapb (bacterial gene) was used, and as positive control
we used the 3-Plex-positive control RNAscope probe, targeting Polr2a, Ppib and
Ubc, both provided by the manufacturer (Advanced Cell Diagnostics). Images were
acquired with a Zeiss LSM 880 with Airyscan with 20x/0,8 Plan-APOCHROMAT.
Image processing was performed using Zen 2.3 and the NIH ImageJ software.
Tissue processing. Mouse embryos were collected at different embryonic stages
(E9.5 to E12.5) and ﬁxed by immersion in 4% paraformaldehyde/PBS (diethyl
pyrocarbonate (DEPC) treated) at 4 C overnight. For RNAscope Multiplex
Fluorescent Assay, mouse embryos were ﬁxed by immersion in 4% paraf-
ormaldehyde/PBS (DEPC treated) at RT for 1 h. Chicken embryos were killed at
different developmental stages (HH17-HH30)57 and ﬁxed by immersion in 4%
paraformaldehyde/PBS (DEPC treated) at RT for 1 h. Afterwards, embryos were
transferred to 25–30% sucrose/PBS-DEPC at 4 C overnight and subsequently
embedded in optimal cutting temperature (OCT) compound and stored at
 80 C. Serial 16-, 20- or 40-mm-thick transverse sections were cut using a
cryostat (MICROM HM560) and collected on SuperFrost Plus slides
(Menzel-Glaeser, Braunschweig, Germany).
Whole mount staining on vibratome sections. Whole mount vibratome
immunostainings were performed as previously described with minor
modiﬁcations58. Brieﬂy, E11.5 embryos were ﬁxed by immersion in 4%
paraformaldehyde (PFA) at 4 C for 6 h, washed with PBS, and embedded in 5.5%
agarose, and sectioned at 500 mm on a vibratome (Leica VT1200S). Afterwards, the
sections were blocked overnight at 4 C in PBS-T (PBS with 1% Triton X-100) with
10% normal donkey serum. Following blocking, the sections were incubated with
primary antibodies diluted in PBS-T with 1% normal donkey serum for 36 h.
Sections were then washed ﬁve times for 30min with PBS-T, and incubated with
secondary antibodies diluted in blocking solution overnight at 4 C. Finally,
sections were washed ﬁve times for 30min at RT with PBS-T and the next day
rinsed with PBS and mounted. Images were acquired on a Nikon AR1 confocal
microscope with 20x/0,75 Plan-Apo l.
qRT-PCR. RNA from tissue was isolated using the RNeasy Mini Kit (Ref:74104).
Subsequently, DNAseI-treated (EN0521, Thermo Scientiﬁc) RNA was reverse-
transcribed into cDNA using either Maxima Reverse Transcriptase (EP0742,
Thermo Scientiﬁc) or SuperScriptVilo (11754-050, Thermo Scientiﬁc). mRNA
expression levels were assessed by qRT-PCR using Fast SYBR Green Master Mix
(00408995, Thermo Scientiﬁc), relative to the expression level of Gapdh or 18S
(for mouse and chicken samples, respectively). For studying mRNA expression
in normoxia and hypoxia conditions, mRNA levels were expressed relative to
the housekeeping gene Rpl13a, due to its stable gene expression under these
conditions59. The qRT-PCR primers used are indicated in Supplementary Table 3.
Isolation of MN columns for qRT-PCR analysis. Explants containing MN
columns from E11.5 WT SC were microdissected via open book preparation
(Supplementary Fig. 7a), followed by a dissociation step using a P-1000 pipette.
Subsequently, the neural component was enriched by removing CD31þ cells using
CD31 MicroBeads (130-097-418, MACS Milteny Biotec) in combination with MS
Columns (130-042-201, MACS Milteny Biotec) following the manufacturer’s
protocol for ‘Isolation of endothelial cells from mouse neonatal brain—Section 2.2.2
(Enrichment of CD31þ cells) (Milteny Biotec)’.
Histology and immunohistochemistry. For immunohistochemistry the following
primary antibodies were used at the indicated dilutions: Isl1 (40.2D6, 1:100,
DSHB), Isl1/2 (39.4D5, 1:200, DSHB), Nkx2.2 (74.5A5, 1:100, DSHB), Olig2
(AB9610, 1:100, Millipore), Pax7 (1:10, DSHB), anti-h/m/r Hif-1a (AF1935, 1:100,
R&D Systems), pAb anti-Carbonic Anhydrase IX/CA9 (NB100-417, 1:100, Novus
Biologicals), TER-119 (MAB1125, 1:100, R&D Systems), rabbit anti-FoxP1
(ab16645, 1:1.000, Abcam), mouse anti-neuroﬁlament-M (RMO 270, 1:1.500,
ThermoFischer), anti-mouse Flt1 (103-M31, 1:100, ReliaTech GmbH), En-1 (4G11,
1:50, DSHB). The secondary antibodies that were used were donkey anti-mouse
Alexa488 (715-545-150, 1:400, Jackson ImmunoResearch), goat anti-mouse
Alexa488 (115-545-146, 1:400, Jackson ImmunoResearch), goat anti-rat Alexa568
(A11077, 1:400, Invitrogen), donkey anti-rabbit Alexa647 (711-605-152, 1:400,
Jackson ImmunoResearch). Blood vessels were visualized using Isolectin GS-IB4
Alexa Fluor 568 conjugate (I21412, 1:250, Invitrogen). Images were collected on a
confocal microscope (Zeiss LSM 510 unit mounted on an Axiovert 200M inverted
microscope) with 10x/0,3 EC Plan-NEOFLUAR Objective and/or with 20x/0,8
Plan-APOCHROMAT and on a Nikon AR1 confocal microscope with 40x/1,3
Plan-Fluor Objective. Image processing was performed using Zen 2011 and the
NIH ImageJ software.
In situ hybridization. Localization of mRNA was performed by ISH as follows:
cryosections were hybridized with digoxigenin (DIG)-labelled antisense riboprobes
(sequence information is provided in Supplementary Table 4). Hybridizations were
carried out overnight at 68 C. Riboprobes (except Shh probes) were detected by an
alkaline phosphatase-coupled anti-digoxigenin antibody (diluted 1:500 or 1:5,000,
Roche Diagnostics, Mannheim, Germany) and the compound nitroblue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP, Promega) was
used as a chromogenic substrate for the alkaline phosphatase reaction. Exposure
times ranged between 1 h and 2 days. No speciﬁc signal was obtained with sense
probes in adjacent representative sections. Localization of Shh-mRNA was
performed by ﬂuorescent ISH (FISH) detection. Hybridization was carried out as
mentioned above. Riboprobes were detected by an anti-digoxigenin-POD, Fab
fragments antibody (diluted 1:500, Roche Diagnostics) and visualized with TSA
Plus Fluorescein Fluorescence System (Perkin Elmer NEL741). Sections were
observed under a ﬂuorescence microscope Zeiss Axiovert 200 equipped with an
AxioCam MRc camera.
Quantiﬁcation of blood vessel density and ingression angles. The analysis
of SC vascularization was always performed at the brachial and thoracic level,
taking as a reference the forelimb of the mouse embryo. Analysis of blood vessel
patterning was done at these levels as the vascularization pattern is similar along
the SC, and brachial and thoracic regions are well established and accepted for
studying neuronal progenitors, as well as their differentiation and migration in the
developing SC13,60.
The percentage of the area covered by blood vessels to the total area of the SC,
or to the MN column area (¼ Isl1/2þ cells) was quantiﬁed using the NIH ImageJ
software. Values were normalized to the respective control (either control
littermates (mouse) or MN column from the non-electroporated SC side
(chicken)). Blood vessel ingression pattern was analysed quantitatively as
previously described12. Brieﬂy, the ﬂoor plate was taken as a reference and given
the value of 0. From there, the angles of ingressing sprouts were measured using
the Angle tool of NIH ImageJ software. Angles were pooled in arcs of 5. Angles,
where the core of MN columns are located (20–55 in mouse and 20–80 in
chicken), were determined by measuring the ventral-most as well as dorsal-most
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point of Isl1þ or Isl1/2þ area in mouse WT or chicken embryos, respectively.
For each experiment at least ﬁve separate transverse SC sections were analysed
per animal. Quantiﬁcation was done blind to the experimental condition. For
better visualization of blood vessels in chicken embryos, using ImageJ the
Segmentation Plugin ‘Simple Neurite Tracer’ was used and traced vessels were
automatically ﬁlled out.
MN quantiﬁcation. The number of total MNs was determined in 16 mm
cryosections of brachial SC at E11.5 by the expression of determined transcription
factors. Total number of MNs was obtained for at least three embryos per genotype
by counting Isl1/2þ and Isl1/2þFoxP1þ cells per section in at least eight
sections per embryo. The number of lateral motor columns was determined by
co-expression of Isl1/2 and FoxP1 in ventro-laterally located cells. The FoxP1
lateral motor columns mean value was expressed as the percentage of the total
number of MNs (Isl1/2þ and Isl1/2þFoxP1þ ).
Image analysis for MN position. We developed a method for determining MN
soma position based on previously published procedures61,62. Coordinates from
each Isl1/2þ or FoxP1þ /Isl1/2þ MN soma were obtained by processing binary
8-bit images using ImageJ software. A Cartesian coordinate system was established
with the zero located at the ventro-lateral left border of the SC, with the y axis
parallel to the ventricle (ventral-dorsal (V-D) axis) and the x axis at the MN ventral
border (lateral-medial (L-M) axis). For reconstructing MN position of WT or
NSE-VEGFtg embryos, data sets were plotted in scatter and contour density graphs
using the bivariative histogram function ‘hist3’ of MATLAB. This function bins
(divides the range of values into a series of intervals) the loaded data into a
10-by-10 grid. The x and y axes were imported as a column vector into MATLAB.
After the data was divided into intervals, a two-dimensional projected view of
intensities was generated. To do so, the data was interpreted as linear spaced
vectors (with the ‘linspace’ function). This consists of an interpretation of the data
as a set of elements: points and lines, which considers proximity and continuity to
visualize a topological graph. For statistical analysis the L-M or V-D distributed
data was represented as boxplots, which boundaries were set at the 25th and 75th
percentile. The median is represented as a line in the boxplot. The whisker length is
set by the Tukey method, which calculates all the values situated 1.5 times the
interquartile distance. Values greater than this range are plotted as individual dots
on the graph. Similarly, for determining differences between densities, the distance
range from the origin, containing 80% of cumulative MN somas, was determined
for every image and represented as boxplots for each x or y distribution.
Cell culture. HBMECs (gift of PD Dr Andreas Fischer, DKFZ Heidelberg,
Germany) were maintained in 0,1% gelatin-coated ﬂasks in Endopan 3 Kit for
endothelial cells (PAN-Biotech, GmbH, Aidenbach, Germany) supplemented with
10% FBS, 100Uml 1 penicillin and 100 mgml 1 streptomycin (both Gibco by
Life Technologies, Grand island, NY, USA) in a 5% CO2 humidiﬁed incubator at
37 C. Cells from passages 6 to 10 were used for the experiments.
Hypoxia-treatment of MN column explants. MN column explants from E11.5
WT SCs were isolated via open book preparation and placed on growth factor-
reduced Matrigel (BD Bioscience) in HBMECs culture medium without VEGF,
FGF-2 and FBS (¼ starvation medium). MN column explants were treated with
150 nM chetomin or solvent (DMSO) for 8 h and then transferred to hypoxic
conditions (1% O2) or maintained in normoxic conditions (20% O2) for further 4 h.
Subsequently, RNA from the MN explants was isolated for qRT-PCR analysis.
Conditioned medium (CM). MN column explants or ingression site (IN) explants
from E11.5 WT SC were microdissected via open book preparation and cultured in
three-dimensional collagen type I (Corning) in HBMECs culture medium without
VEGF, FGF-2 and FBS (¼ starvation medium). MN-, IN-CM or control medium
(without explants) were collected after 48 h and used right away.
Quantiﬁcation of human VEGF protein levels by ELISA. To quantify human
VEGF protein levels in NSE-VEGFtg mice, SC from E11.5 NSE-VEGFtg embryos or
control littermates were isolated and total cellular protein was extracted using
ELISA-extraction buffer (100mM Tris pH7.5, 150mM NaCl, 1mM EDTA,
1% Triton X-100, 0,5% Sodiumdeoxycholate, Protease Inhibitor Cocktail Tablets
(Roche Diagnostics)). Subsequently, enzyme-linked immunosorbent assay (ELISA)
was performed according to the manufacturer’s instructions (R&D Systems,
Quantikine DVE00).
Quantiﬁcation of mouse VEGF protein levels by ELISA. Quantiﬁcation of mouse
VEGF protein levels in MN explant and MN-CM was performed according to
the manufacturer’s instructions (R&D Systems, Quantikine MMV00). Brieﬂy,
MN explants of two E11.5 SCs were cultured in 250 ml starvation medium
(see above) for 48 h. Total cellular protein of MN explants was extracted using
ELISA-extraction buffer. MN-CM (1:5 dilution) was directly subjected to the assay.
Quantiﬁcation of mouse Flt1 protein levels by ELISA. Quantiﬁcation of mouse
Flt1 protein levels was performed according to the manufacturer’s instructions
(R&D Systems, Quantikine MVR100). Brieﬂy, MN explants of two E11.5 SCs were
cultured in 250 ml starvation medium, either in absence or presence of 10Uml 1
heparin (H4784, Sigma-Aldrich) for 20 h. Total cellular protein of MN explants
was extracted using ELISA-extraction buffer. MN-CM was directly subjected to
the assay.
Transwell migration assay. Upon reaching conﬂuency HBMECs were starved for
5 h in HBMECs starvation medium, then trypsinized and plated at 4 104 cells/
insert in a Transwell Permeable Support (6.5mm Insert, 24-well plate, 3.0 mm
polycarbonate membrane, tissue culture-treated polystyrene, Costar (Ref: 3415))
with control CM, control CMþ 50 ngml 1 VEGF, MN-CM or IN-CM (all with or
without adding 1 mgml 1 recombinant mouse Flt1/Fc) in the lower compartment.
Inserts were coated before with 10 mgml 1 ﬁbronectin (F0895, Sigma-Aldrich).
After 20 h cells were ﬁxed and nuclei were stained. Migration of endothelial cells on
the other side of the ﬁlter was calculated by counting the number of nuclei per ﬁeld
of view. Five ﬁeld of views were counted per condition. Quantiﬁcation was done
blind to the experimental condition.
Tube formation assay. Tube formation assays were performed in m-Slide
Angiogenesis wells (ibidi GmbH, Germany) using 10 ml of growth factor-reduced
Matrigel (BD Bioscience) per well and allowed to polymerize for 30min at 37 C.
Subsequently, 1 104 HBMECs were resuspended in control CM, control
CMþ 50 ngml 1 VEGF, MN-CM or IN-CM (all with and without adding
1 mgml 1 recombinant mouse Flt1/Fc), and 50 ml of cell suspension were added
per well. Cells were incubated for 4–6 h in a humidiﬁed chamber at 37 C, 5% CO2.
Images were acquired using a microscope Zeiss Axiovert 200M with 5x/0,16 EC
Plan-NEOFLUAR Objective. Tube length was quantiﬁed using Angiogenesis
Analyzer for ImageJ (Gilles Carpentier. ImageJ contribution: angiogenesis
analyzer. ImageJ News, 5 October 2012) and number of branches were counted
manually. Quantiﬁcation was done blind to the experimental condition.
Tube-touching assay. Tube-touching assays were performed in m-Slide
Angiogenesis wells as described for the tube formation assay except for the addition
of either MN explants, IN explants or MN explants from NSE-VEGFtg embryos to
cell suspension. 50ml of HBMECs suspension (prepared as above) including
explants were added per well (3–4 explants per well). Cells together with the
explants were incubated for 4–6 h in a humidiﬁed chamber at 37 C, 5% CO2.
Images were acquired using a microscope Zeiss Axiovert 200M with 5x/0,16 EC
Plan-NEOFLUAR Objective. Numbers of tubes touching the explant were counted
manually. Quantiﬁcation was done blind to the experimental condition.
Time-lapse video microscopy. Time-lapse video microscopy was performed for
the tube-touching assays. Formation of tubular structures at/around explants were
captured every 10min for an overall duration of 410min using a Andor/Nikon
Ti-TuCam microscope equipped with a Nikon Plan Fluor 10x NA 0.3 objective and
a environmental box for controlling CO2 (5%) and temperature (37 C).
Scratch assay. HBMECs (2,4 104 cells) were seeded into two chambers
separated by a divider (Culture-Insert 2 Well in m-Dish 35mm, high ibiTreat:
ready to use, tissue culture treated, sterilized, ibidi GmbH). For monitoring cell
migration, CellTracker Red CMPTX ﬂuorescent dye (Life Technologies) was used.
The divider was removed once cells formed a conﬂuent monolayer. MN explants
and IN explants were isolated from E11.5 WT SC via open book preparation,
analogous for MN explants of NSE-VEGFtg embryos. The explants were placed in
the gap. Quantiﬁcation of the relative gap closure was assessed by measuring the
area not covered by HBMECs after 6 h, 20 h and 30 h after initiation of the assay
and expressed as percentage of cell coverage of initial scratch area. Quantiﬁcation
was done blind to the experimental condition.
In silico analysis. Cytoscape (an open source bioinformatics software platform,
version 3.4.0)28 with GeneMANIA63 plugin (version: 3.4.1) was used to generate a
list of potential VEGF regulators. VEGF was queried for mouse and human
data separately to obtain two lists (one for each organism). Co-expression,
Co-localization, Genetic interactions, Pathway, Physical interactions, Predicted and
Others were chosen as Interaction Networks. The 100-top ranked genes were found
using equal weighting for mouse and human data separately. Next, a combined list
was generated by merging the genes from both lists. Genes that appear in both lists
were counted once. Then they were presented to an already available gene
expression data set of SC MNs at E11.5 (ref. 29) (accession identiﬁer: GSE45807).
The CEL ﬁles were downloaded and processed using statistical language R64
(version: 3.3.1). To perform background subtraction, quantile normalization and
summarization the package oligo (version: 1.36.1) was used. To classify expression
levels of the genes in question a probability distribution of expression levels for a
list of housekeeping genes65 (Supplementary Data 5) was calculated. The genes
with expression level higher than the third or the ﬁrst quartile were considered as
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overexpressed or expressed, respectively. All other genes were classiﬁed as
underexpressed. To perform an enrichment analysis for stratiﬁed gene lists
Enrichr30 was used. The enriched signatures for NCI-Nature 2016 library are
presented in the form of a bar graph and clustergram. The same approach as
described above was also performed for ﬁnding potential regulators of Flt1.
Statistical analysis. Statistical analysis was performed using GraphPad
Prism (6.0) (GraphPad Software Inc.). All data are expressed as mean±s.e.m.
For comparison between two groups, unpaired Student’s t-test was used. For
comparisons between multiple groups, one-way analysis of variance using Tukey’s
multiple comparisons test was performed, and P values were adjusted to account
for multiple comparisons. For MN distribution statistical analysis Mann–Whitney
test was used, due to different variances between groups. Statistical signiﬁcance was
deﬁned as *Po0.05, **Po0.01 ***Po0.001, ****Po0.0001. The experiments were
not randomized. The investigator was blinded for all analysis and quantiﬁcations.
No samples or animals were excluded from the analysis.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information Files or
from the corresponding author upon reasonable request.
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